Global Orthobiologics Market to Grow with a CAGR of 5.10% through 2028
Rising prevalence of road accidents are expected to
drive the Global Orthobiologics Market in the forecast period 2024-2028.
According to TechSci Research report, “Global
Orthobiologics Market – Global Industry Size, Share, Trends, Competition
Forecast & Opportunities, 2028”, the Global Orthobiologics Market stood
at USD 5.89 billion in 2022 and is anticipated to grow with a CAGR of 5.10% in
the forecast period, 2024-2028. The significant growth drivers of the
orthobiologics market include a rising incidence of sports injuries, road
accidents, osteoarthritis, and an increasing preference for minimally invasive
surgical approaches. According to the 2020 statistics from the United Kingdom
National Health Service, conditions like tennis elbow affect approximately 1-3%
of the population, translating to about four to seven cases per 1000 individuals
annually. This high prevalence of sports-related injuries is boosting the
demand for orthobiologics as an effective treatment option, thereby propelling
market growth.
Furthermore, the global increase in the aging
population and the prevalence of obesity are contributing to a higher incidence
of osteoarthritis and musculoskeletal disorders. The World Health Organization
reported that in 2021, around 1.71 billion people worldwide had musculoskeletal
conditions. Low back pain, in particular, had the highest prevalence, affecting
568 million individuals. In the United Kingdom, more than 20 million people,
approximately one-third of the population, live with musculoskeletal conditions
such as arthritis and low back pain. These conditions significantly impact the
quality of life and contribute to the burden of illness and disability. With
the growing number of musculoskeletal injuries, there is a corresponding rise
in demand for orthobiologics, which is expected to fuel market growth. Additionally,
the introduction of new orthobiologic products and strategic initiatives by key
market players is anticipated to further boost market expansion. For instance,
Ventris Medical launched Allocell AF in April 2021, a next generation
osteoinductive fiber allograft designed to enhance intra-operative handling and
improve biological responsiveness at the site of injury. However, the high cost
associated with biologic-based treatments and the preference for alternative
therapies pose potential hindrances to market growth.
Orthobiologics refer to a category of biological
substances or materials that are used to promote the healing, regeneration, or
replacement of musculoskeletal tissues, such as bones, cartilage, tendons, and
ligaments. These materials are derived from natural sources or can be produced
synthetically and are utilized in orthopedic and musculoskeletal medicine to
treat a range of conditions and injuries. Here are some key applications of
orthobiologics: Bone Grafting: Orthobiologics are often employed in bone grafting
procedures to stimulate bone growth and repair. Autologous bone grafts (taken
from the patient's own body), allografts (from donors), or synthetic bone
substitutes can be augmented with orthobiologics like growth factors, stem
cells, or bone morphogenetic proteins (BMPs) to enhance the fusion and healing
of fractured or damaged bones. Cartilage Repair: Orthobiologics play a crucial
role in the treatment of cartilage injuries and degenerative conditions like
osteoarthritis. They can be used in conjunction with procedures like
microfracture, autologous chondrocyte implantation (ACI), or osteochondral
grafting to stimulate cartilage regeneration and reduce pain. Tendon and
Ligament Repair: Orthobiologics, particularly platelet-rich plasma (PRP), are
applied in the management of tendon and ligament injuries. PRP injections can
promote tissue healing, reduce inflammation, and enhance the recovery of
structures like the Achilles tendon or anterior cruciate ligament (ACL). Spinal
Fusion: Orthobiologics are frequently utilized in spinal fusion surgeries to
stimulate bone growth and facilitate the fusion of vertebrae. BMPs, in
particular, have been approved for this application, reducing the need for
traditional bone grafts. Soft Tissue Repair: Injuries to soft tissues like
tendons and ligaments can benefit from orthobiologic treatments. These
substances can enhance the healing process, reduce pain, and improve function
following injuries.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global
Orthobiologics Market”
The Global Orthobiologics Market is driven by several
key factors:
Increasing Incidence of Musculoskeletal Conditions:
The growing prevalence of musculoskeletal disorders such as osteoarthritis,
osteoporosis, and sports-related injuries is a significant driver. As the
global population ages and lifestyles become more sedentary, the demand for
orthobiologic treatments to alleviate pain and restore function is on the rise.
Preference for Minimally Invasive Procedures: Patients and healthcare providers
are increasingly favoring minimally invasive orthopedic procedures over traditional
open surgeries. Orthobiologics, which can be administered via injections or
arthroscopic techniques, align with this trend, offering reduced recovery
times, shorter hospital stays, and less post-operative pain. Advancements in
Biotechnology: Continuous advancements in biotechnology have led to the
development of more sophisticated orthobiologic products. These innovations
include the isolation of growth factors, stem cell therapies, and tissue
engineering techniques that enhance the effectiveness of regenerative
treatments. Sports-Related Injuries: The rise in sports participation and
athletic activities has led to a higher incidence of sports-related injuries,
including ligament tears and cartilage damage. Orthobiologics, especially when
combined with minimally invasive procedures, are increasingly used to treat
athletes and active individuals, driving market growth. Rising Geriatric
Population: The aging global population is at a higher risk of musculoskeletal
conditions, including osteoarthritis and fractures. As the elderly seek
effective treatments to maintain their mobility and independence, the demand
for orthobiologics continues to grow. Regulatory Support: Regulatory bodies are
adapting to accommodate orthobiologic therapies, streamlining approval
processes and providing clearer guidelines for manufacturers. This has reduced
barriers to market entry and encouraged innovation. Patient-Centric Care:
Patients are becoming more proactive in their healthcare decisions, seeking
treatments that align with their preferences for less invasive, regenerative
therapies. Orthobiologics, with their potential to improve quality of life,
resonate with this patient-centric approach. Technological Advancements:
Advancements in diagnostic imaging and surgical techniques have improved the
precision of orthobiologic treatments. This has made orthobiologics more
attractive for both patients and healthcare providers. Increased Research and
Clinical Trials: The investment in research and clinical trials to demonstrate
the safety and efficacy of orthobiologics has expanded, further establishing
their credibility and driving their adoption.
These drivers collectively contribute to the rapid growth of the Global
Orthobiologics Market, with the potential to revolutionize orthopedic and
musculoskeletal care, offering patients innovative and minimally invasive
solutions for various conditions and injuries.
The Global Orthobiologics Market is segmented into product,
application, end user, regional distribution, and company.
Based on application, the market is segmented Osteoarthritis
and Degenerative Arthritis , Spinal Fusion, Soft-tissue Injuries, Others. The Osteoarthritis
and Degenerative Arthritis segment is expected to rise in the forecast period.
This is attributed due to he growing geriatric population, increasing product
launches, and the rise in strategic initiatives by key market players are
expected to further drive market growth. Additionally, the product launches
will expand the product offering in the studied segment with more efficient
products, thus driving the segment. For instance, in April 2021, Organicell
Regenerative Medicine, Inc. received the approval of the US Food and Drug
Administration (FDA) for the Investigational New Drug (IND) application for
Zofin in treating knee osteoarthritis. Zofin is an acellular, biologic
therapeutic derived from perinatal sources and is manufactured to retain
naturally occurring microRNAs,
Based on region, the market is segmented into North
America, Europe, Asia Pacific, Central & South America, Middle East
& Africa. The North America segment
was dominated the market in 2022. This is due to the rising incidence of
osteoarthritis, growing geriatric and obese population, and increasing
prevalence of minimally surgical procedures. In addition, rising product
launches and strategic initiatives by key market players may also contribute to
market growth. Additionally, growing product launches in the region contribute
to market growth. For instance, in February 2021, Signature Biologics LLC
received the Food and Drug Administration (FDA) approval for an IND Application
to proceed with the study of Signature Cord Prime in patients with symptomatic
osteoarthritis (OA) of the knee. Signature Cord Prime is a cryopreserved, human
umbilical cord tissue allograft for managing symptomatic knee osteoarthritis.
Major companies operating in Global
Orthobiologics Market are:
- Sanofi SA
- Stryker Corporation
- Zimmer Biomet
- Seaspine Holdings Corporation
- Medtronic PLC
- DePuy Synthes
- Bioventrus
- Globus Medical
- Arthrex Limited
- Orthofix International
Download Free Sample Report
Customers can also request for 10%
free customization on this report.
“The Global Orthobiologics Market is driven by several
compelling factors that collectively contribute to its rapid growth and
innovation in the healthcare industry. The growing prevalence of
musculoskeletal disorders such as osteoarthritis, osteoporosis, and
sports-related injuries is a significant driver. As the global population ages
and lifestyles become more sedentary, the demand for orthobiologic treatments
to alleviate pain and restore function is on the rise, propell the growth of Global
Orthobiologics Market. Additionally, the rise in sports participation and
athletic activities has led to a higher incidence of sports-related injuries,
including ligament tears and cartilage damage. Orthobiologics, especially when
combined with minimally invasive procedures, are increasingly used to treat
athletes and active individuals, driving market growth contributes to foster
the demand for Global Orthobiologics Market in the forecast period” said Mr.
Karan Chechi, Research Director with TechSci Research, a research-based management
consulting firm.
“Orthobiologics Market - Global
Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By
Product (Viscosupplementation Products, Demineralized Bone Matrices, Synthetic
Orthobiologics, Bone Morphogenic Protein, Allografts, and Others), By
Application (Osteoarthritis and Degenerative Arthritis, Spinal Fusion,
Soft-tissue Injuries, and Others), By End User (Hospitals, Orthopedic Clinics,
and Ambulatory Care Centers, Academic and Research Institutes, and Dental
Clinics and Facilities), By Region and Competition” has evaluated
the future growth potential of Global Orthobiologics Market and provides
statistics & information on market size, structure and future market
growth. The report intends to provide cutting-edge market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Orthobiologics Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com